| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 571.97 KB | Adobe PDF |
Authors
Advisor(s)
Abstract(s)
Introdução: A doença de Parkinson é um desafio cada vez maior para os cuidados de
saúde. Constitui a segunda doença neurodegenerativa mais prevalente na população
mundial, a seguir à doença de Alzheimer, sendo uma causa importante de
incapacidade. Assim, consome cada vez mais recursos aos sistemas de saúde, aos
doentes e suas famílias, aumentando o impacto social e económico.
Objetivo: Analisar os custos associados às terapêuticas dirigidas para a doença de
Parkinson.
Métodos: Realizou-se uma revisão da literatura, tendo sido usada a base de dados
PubMed com as palavras-chave: Doença de Parkinson; Terapêutica; Tratamento;
Custos. Depois, foram selecionados os artigos adequados à pesquisa e retirados os
dados para uma tabela de extração de dados.
Resultados: Foram inicialmente obtidos 418 resultados. Após eliminação de duplicados
ficaram 232. Após análise de título e resumo de cada um, sobraram 129 artigos.
Posteriormente, lidos os artigos completos, foram selecionados 34. Após análise dos
artigos, verificou-se que entre os fármacos levodopa, biperideno e amatadina, o mais
económico é o biperideno; a estimulação cerebral profunda é uma terapêutica custoefetiva em relação a medicação apenas; a infusão intestinal de levodopa/carbidopa não
se mostrou rentável, mas em conjunto com o opicapone pode reduzir-se os seus custos.
A adição do opicapone a levodopa/carbidopa é mais custo-efetiva relativamente à
adição de epicapone a levodopa/carbidopa. A prescrição de rotigotina e apomorfina
mostrou reduzir custos associados a cuidados de saúde secundários. A reabilitação com
programas de exercícios especializados, nomeadamente realidade virtual, mostrou ser
mais custo-efetiva que os cuidados habituais prestados.
Conclusão: A DP é dispendiosa e como tal é importante o controlo sintomático precoce
da doença com terapêuticas médicas/médico-cirúrgicas e reabilitação custo-efetivas, de
modo a melhorar a qualidade de vida dos doentes e, ao mesmo tempo, salvaguardar
recursos na saúde.
Introduction: Parkinson's disease is an increasing challenge for healthcare. It is the second most prevalent neurodegenerative disease in the world population, after Alzheimer's disease, being an important cause of disability and consuming more and more resources to health systems, patients and their families, increasing the social and economic impact. Objective: to analyze the costs associated with therapies for Parkinson's disease. Methods: A literature review was carried out, using the PubMed database with the keywords: Parkinson's disease; Therapy; Treatment; costs. Then, the articles suitable for the research were selected and the data collected for a data extraction table. Results: Initially, 418 results were obtained, after elimination of duplicates, there were 232, then after analyzing the title and abstract of each one, 129 articles remained; later, after reading the complete articles, 34 were selected. After analyzing the articles, it was found that among the drugs levodopa, biperideno and amantadine, the most economical is biperideno; deep brain stimulation is a cost-effective therapy over medication alone; intestinal infusion of levodopa/carbidopa did not prove to be cost effective, but together with opicapone its costs can be reduced; adding opicapone to levodopa/carbidopa is more cost-effective than adding epicapone to levodopa/carbidopa; prescribing rotigotine and apomorphine has been shown to reduce costs associated with secondary health care; rehabilitation with specialized exercise programs, namely virtual reality, proved to be more cost-effective than the usual care provided. Conclusion: PD is expensive and, as such, early symptomatic control of the disease with cost-effective medical/medical-surgical therapies and rehabilitation is important, in order to improve patients' quality of life and, at the same time, safeguard health resources.
Introduction: Parkinson's disease is an increasing challenge for healthcare. It is the second most prevalent neurodegenerative disease in the world population, after Alzheimer's disease, being an important cause of disability and consuming more and more resources to health systems, patients and their families, increasing the social and economic impact. Objective: to analyze the costs associated with therapies for Parkinson's disease. Methods: A literature review was carried out, using the PubMed database with the keywords: Parkinson's disease; Therapy; Treatment; costs. Then, the articles suitable for the research were selected and the data collected for a data extraction table. Results: Initially, 418 results were obtained, after elimination of duplicates, there were 232, then after analyzing the title and abstract of each one, 129 articles remained; later, after reading the complete articles, 34 were selected. After analyzing the articles, it was found that among the drugs levodopa, biperideno and amantadine, the most economical is biperideno; deep brain stimulation is a cost-effective therapy over medication alone; intestinal infusion of levodopa/carbidopa did not prove to be cost effective, but together with opicapone its costs can be reduced; adding opicapone to levodopa/carbidopa is more cost-effective than adding epicapone to levodopa/carbidopa; prescribing rotigotine and apomorphine has been shown to reduce costs associated with secondary health care; rehabilitation with specialized exercise programs, namely virtual reality, proved to be more cost-effective than the usual care provided. Conclusion: PD is expensive and, as such, early symptomatic control of the disease with cost-effective medical/medical-surgical therapies and rehabilitation is important, in order to improve patients' quality of life and, at the same time, safeguard health resources.
Description
Keywords
Custos Doença de Parkinson Terapêutica Tratamento